Michaëla Fontenay - Concepedia

Author

Michaëla Fontenay

Also Known As

Beatrice Deygas, F. Chermat, M Fontenay, M Fontenay-Roupie, M. Fontenay, M. Fontenay-Roupie, M. Fontenay‐Roupie, Michaela Fontenay, Michaela Fontenay-Roupie, Michaela Fontenay‐Roupie

339

Publications

20K

Citations

H-Index

131

Concepts

All Affiliations

Inserm Université Paris Cité Assistance Publique – Hôpitaux de Paris Institut Cochin Hôpital Cochin

About

Michaëla Fontenay is an author at Inserm specializing in medicine, hematology, and cell biology.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	30	45	5.8K
2	Health Sciences	13	15	1.1K
3	Public Health	4	4	937
4	Natural Sciences	3	3	64
5	Biochemistry	1	1	32

Michaëla Fontenay

127

Publications

13.6K

Citations

H-Index

Page 1

	Year	Citations
Mutation in <i>TET2</i> in Myeloid Cancers François Delhommeau, Sabrina Dupont, Véronique Della Valle, New England Journal of Medicine	2009	1.7K
Elevated Calprotectin and Abnormal Myeloid Cell Subsets Discriminate Severe from Mild COVID-19 Aymeric Silvin, Nicolas Chapuis, Garett Dunsmore, Cell Mild Covid-19Hematological MalignancyHematologyImmunologyPathology	2020	898
TET2 Inactivation Results in Pleiotropic Hematopoietic Abnormalities in Mouse and Is a Recurrent Event during Human Lymphomagenesis Cyril Quivoron, Lucile Couronné, Véronique Della Valle, Cancer Cell Recurrent EventLymphoid NeoplasiaLymphocyte DevelopmentMalignant Blood DisorderT-regulatory Cell	2011	884
Molecular International Prognostic Scoring System for Myelodysplastic Syndromes Elsa Bernard, Heinz Tuechler, Peter L. Greenberg, NEJM Evidence Mixed-phenotype Acute LeukemiaPrognosisGenetic EpidemiologyDiagnosisPathology	2022	746
Implications of TP53 allelic state for genome stability, clinical presentation and outcomes in myelodysplastic syndromes Elsa Bernard, Yasuhito Nannya, Robert P. Hasserjian, Nature Medicine Hematological MalignancyChromatinGenome StabilityMedicineMixed-phenotype Acute Leukemia	2020	606
Prognostic Score Including Gene Mutations in Chronic Myelomonocytic Leukemia Raphaël Itzykson, Olivier Kosmider, Aline Renneville, Journal of Clinical Oncology	2013	537
Impact of TET2 mutations on response rate to azacitidine in myelodysplastic syndromes and low blast count acute myeloid leukemias Raphaël Itzykson, Olivier Kosmider, Thomas Cluzeau, Leukemia Hematological MalignancyMedicineMixed-phenotype Acute LeukemiaImmunologyHematology	2011	464
TET2 mutation is an independent favorable prognostic factor in myelodysplastic syndromes (MDSs) Olivier Kosmider, Véronique Gelsi‐Boyer, Meyling Cheok, Blood	2009	269
Clonal architecture of chronic myelomonocytic leukemias Raphaël Itzykson, Olivier Kosmider, Aline Renneville, Blood	2013	264
TP53 mutation status divides myelodysplastic syndromes with complex karyotypes into distinct prognostic subgroups Detlef Haase, Kristen E. Stevenson, Donna Neuberg, Leukemia	2019	252

Page 1